Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram oxalate + transcutaneous vagus nerve stimulation
- Development stage
- Unknown
- Lead developer
- Xijing Hospital
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Escitalopram oxalate + transcutaneous vagus nerve stimulation is a combination therapy being investigated for the treatment of major depressive disorder (MDD) and comorbid rheumatoid arthritis (RA). Escitalopram oxalate is an FDA-approved small molecule antidepressant that acts as a selective serotonin reuptake inhibitor (SSRI) by binding to the serotonin transporter (SERT), thereby increasing the availability of serotonin in the synaptic cleft. The transcutaneous vagus nerve stimulation (taVNS) component is a non-invasive neuromodulation device that delivers electrical pulses to the auricular branch of the vagus nerve. This combination aims to leverage the antidepressant effects of escitalopram alongside the potential anti-inflammatory and autonomic-modulating effects of vagus nerve stimulation to treat both the psychiatric and physical symptoms of the dual diagnosis. The treatment protocol is currently being studied in clinical trials led by Xijing Hospital.
- Brand names
- Lexapro
- Other names
- escitalopram oxalate + taVNSescitalopram oxalate + VNSescitalopram oxalate combined with transcutaneous auricular vagus nerve stimulation
02
Targets
SERT (Sodium-dependent serotonin transporter)ABVN (Auricular branch of the vagus nerve)
Beyond the preview
Go deeper on escitalopram oxalate + transcutaneous vagus nerve stimulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram oxalate + transcutaneous vagus nerve stimulation.